구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ocrelizumab |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Multiple Sclerosis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel therapeutic peptide, has shown promise in restoring BBB integrity, in both preclinical and clinical settings, offering |
Positioning Known limitation | resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed |
MoA Mechanism | target pathways relevant to MS pathophysiology, including Th17/Treg balance, Wnt-β-catenin signaling |
MoA Biomarker | biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease |
PK/PD Half-life | 26 h |
PK/PD Animal (cat.) | Human, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Human, In vitro |
Toxicology Major finding | hepatotoxicity was identified in three patients, according to the scale of the internationa |
Clinical Safety signal | hepatotoxicity was identified in three patients, according to the scale of the internationa |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Ocrelizumab |
Overview Company | Genentech, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Multiple Sclerosis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel therapeutic peptide, has shown promise in restoring BBB integrity, in both preclinical and clinical settings, offering |
Positioning Known limitation | resistance to these therapies inevitably develops in patients, and thus novel antibody approaches are needed |
MoA Mechanism | target pathways relevant to MS pathophysiology, including Th17/Treg balance, Wnt-β-catenin signaling |
MoA Biomarker | biomarker-guided retreatment, infection-risk mitigation, and regimen adaptation for non-malignant disease |
PK/PD Half-life | 26 h |
PK/PD Animal (cat.) | Human, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Human, In vitro |
Toxicology Major finding | hepatotoxicity was identified in three patients, according to the scale of the internationa |
Clinical Safety signal | hepatotoxicity was identified in three patients, according to the scale of the internationa |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교